Verition Fund Management
TRIB

Verition Fund Management’s Trinity Biotech TRIB Stock Holding History

Verition Fund Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,418
Closed -$15K – 1369
2019
Q3 		$15K Hold
2,418
– – ﹤0.01% 1008
2019
Q2 		$22K Hold
2,418
– – ﹤0.01% 1029
2019
Q1 		$34K Hold
2,418
– – ﹤0.01% 1053
2018
Q4 		$28K Hold
2,418
– – ﹤0.01% 780
2018
Q3 		$48K Hold
2,418
– – ﹤0.01% 1210
2018
Q2 		$60K Buy
+2,418
New +$58.2K ﹤0.01% 1036

Other funds holding TRIB

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return
FM
Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ARM
Adirondack Research & Management Guilderland, New York $82.2M AUM 63.78% 1-Year Est. Return

Verition Fund Management's TRIB Position: Q4 2019 in Review

Verition Fund Management sold out of Trinity Biotech (TRIB) in Q4 2019, closing a stake of 2,418 shares — an estimated $15K sold.

Verition Fund Management first reported a position in TRIB in Q2 2018 and held it in 6 quarters. The position peaked at $60K in Q2 2018. 26 funds tracked by Wall St. Rank hold TRIB as of Q4 2019.

  • Verition Fund Management reported no remaining Trinity Biotech position as of Q4 2019 after selling out during the quarter.
  • Verition Fund Management sold 2,418 Trinity Biotech shares in Q4 2019, an estimated $15K.
  • Verition Fund Management first reported a position in Trinity Biotech in Q2 2018 and held it in 6 quarters.
  • Verition Fund Management's Trinity Biotech position peaked at $60K in Q2 2018.
  • 26 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2019.

Based on Verition Fund Management's 13F filing for Q4 2019, filed 14 Feb 2020.